重组人粒细胞集落刺激因子 治疗化疗后白细胞减少的有效性分析

    The efficacy of recombinant human granulocyte colony-stimulating factor in the treatment of leucopenia after chemotherapy

    • 摘要: 目的:评价重组人粒细胞集落刺激因子(rhG-CSF)对肿瘤患者化疗后白细胞减少的有效性。方法:将62例恶性肿瘤化疗后白细胞减少的患者随机分为对照组和观察组,各31例。对照组予微达康颗粒2袋/次,3次/天,连用1周后改为1袋/次,3次/天,口服;观察组予rhG-CSF 150 g,皮下注射,1次/天,2组均直至白细胞恢复正常范围后停药。结果:2组均能使化疗后白细胞下降的患者恢复至正常范围,观察组白细胞回升至正常范围的时间少于对照组(P0.05~P0.01)。结论:rhG-CSF对治疗恶性肿瘤化疗所致的白细胞减少作用较好,值得临床推广应用。

       

      Abstract: Objective:To evaluate the efficacy and safety of recombinant human granulocyte colony-stimulating factor(rhG-CSF) in the treatment of leucopenia after chemotherapy.Methods:Sixty-two patients with leucopenia after chemotherapy were randomly divided into observation group and control group(31 cases each group).The 150 g of rhG-CSF were subcutaneously injected into the observation group once a day.The control group were treated with Weidakang particles two bags per time three times a day for one week,then one bag per time three times a day by oral.The drug was stopped when the level of leukocyte arrived at normal.Results:The treatment with rhG-CSF or Weidakang particles were able to make the level of leukocyte after chemotherapy recover normal range,the recovery time in observation group was less than that in control group(P0.05 to P0.01).Conclusions:The rhG-CSF for treating leucopenia caused by malignant tumor after chemotherapy is good,which is worthy of clinical application.

       

    /

    返回文章
    返回